News

1 to 9 of 70 results

Cyclenium signs drug discovery and collaboration agreement with Fundación MEDINA

Cyclenium signs drug discovery and collaboration agreement with Fundación MEDINA

23-02-2015

Emerging pharma company Cyclenium, focused on proprietary macrocyclic chemistry, has signed a drug discovery…

Antibiotics and Infectious diseasesBiotechnologyCycleniumFundacion MEDINAResearchSpain

Motif Bio to list on AIM to progress novel antibiotic

Motif Bio to list on AIM to progress novel antibiotic

02-02-2015

Motif Bio has announced its intention to list on the alternative Investment Market to raise at least…

Antibiotics and Infectious diseasesBiotechnologyFinancialMotif BiosciencesUK

Holger Zimmermann replaces founding chief executive of AiCuris

Holger Zimmermann replaces founding chief executive of AiCuris

21-01-2015

AiCuris, a company formed by experts from Bayer's virology and bacteriology research divisions, is to…

AiCurisAntibiotics and Infectious diseasesBiotechnologyBoardroomGermany

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

Motif Biosciences agrees to merge with company holding IP to potential MRSA antibiotic

19-01-2015

Motif Biosciences, a partner of life science business developer Amphion Innovations, has entered into…

Amphion InnovationsAntibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsMotif BiosciencesMRSA antibioticUSA

Harvoni scores another victory with inclusion on Prime’s preferred list

Harvoni scores another victory with inclusion on Prime’s preferred list

13-01-2015

US pharmacy Prime Therapeutics has agreed to provide hepatitis C drug Harvoni (ledipasvir/sofosbuvir)…

Antibiotics and Infectious diseasesBiotechnologyGileadHarvoniPricingUSA

Cempra announces positive results from Phase III trial of solithromycin in bacterial pneumonia

Cempra announces positive results from Phase III trial of solithromycin in bacterial pneumonia

05-01-2015

Antibiotic specialist Cempra has announced positive top-line results from its pivotal Phase III trial…

Antibiotics and Infectious diseasesBiotechnologyCempraResearchsolithromycinUSA

Phylogica inks $142 million license deal with Genentech

Phylogica inks $142 million license deal with Genentech

22-12-2014

Australian drug discovery firm Phylogica has extended its collaboration with Genentech, the biotech subsidiary…

Antibiotics and Infectious diseasesAustraliaBiotechnologyGenentechLicensingPhylogicaResearchRoche

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

17-12-2014

Biopharma company Emergent BioSolutions has acquired the EV-035 series of molecules from Evolva Holding.

Antibiotics and Infectious diseasesBiotechnologyEmergent BioSolutionsEvolvaLicensingResearchUSA

1 to 9 of 70 results

Back to top